莫基奧症候群治療藥物的市場規模、佔有率和成長分析（按治療方法、疾病類型、分銷管道和地區）：產業預測（2025-2032）

2023年全球莫基奧症候群治療藥物市場規模為1.556億美元，從2024年的1.6462億美元成長到2032年的2.5845億美元，在預測期內（2025年-2032年）預計複合年成長率為5.8% 。

Morquio 症候群被歸類為黏多醣症(MPS IV)，是一種罕見的遺傳代謝性疾病，主要影響骨骼，其特徵是無法代謝Glico。由於患病率上升、政府和企業支持的增加以及對解決併發症的專用藥物的需求不斷增加，全球莫基奧症候群治療藥物市場正在顯著成長。醫療保健成本上升和技術進步推動了製造商之間的策略合併和聯盟，旨在增加治療選擇。臨床試驗也在擴大，從 2022 年到 2028 年提供了利潤豐厚的機會。然而，報銷政策不足和製造成本高昂等挑戰可能會阻礙市場擴張，再加上大眾對治療方案的認知較低，這可能會阻礙市場的擴張。

目錄

介紹

• 分析目的
• 市場範圍
• 定義

分析方法

• 資訊採購
• 次要/主要資料方法
• 市場規模預測
• 市場假設與約束

執行摘要

• 市場概況及展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制因素和挑戰
• 波特分析

主要市場考慮因素

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場魅力指數（2024）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析
• 技術分析
• 監管分析
• 專利分析
• 案例研究

莫基奧症候群治療藥物的全球市場規模和複合年成長率：按治療方法分類（2025-2032）

• 市場概況
• 酵素替代療法
• 其他

莫基奧症候群治療藥物的全球市場規模和複合年成長率：按疾病類型分類（2025-2032）

• 市場概況
• 莫爾基奧A
• 莫爾基奧B

莫基奧症候群治療藥物的全球市場規模和複合年成長率：按分銷管道分類（2025-2032）

• 市場概況
• 醫院藥房
• 零售藥房
• 網路藥房
• 其他

Morquio症候群治療藥物全球市場規模及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭格局

• 前5名企業對比
• 主要企業市場定位（2024年）
• 主要企業採取的策略
• 近期市場趨勢
• 主要企業市場佔有率（2024年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2022-2024）

主要企業簡介

• BioMarin 製藥公司（美國）
• 健贊公司（美國）
• Shire plc (Ireland)
• JCR製藥有限公司（日本）
• 賽諾菲（法國）
• Sangamo Therapeutics（美國）
• ArmaGen, Inc.（美國）
• 綠十字株式會社（韓國）
• Concert Pharmaceuticals Inc.（美國）
• 亞力兄製藥公司（美國）
• 諾和諾德公司（丹麥）
• 禮來公司（美國）
• 勃林格殷格翰國際有限公司（德國）
• AstraZeneca (UK)
• 安進公司（美國）
• 默克公司（德國）
• Actelion 製藥股份有限公司（瑞士）
• 比康（印度）
• Ultragenyx 製藥公司（美國）
• Enzyvant Therapeutics Inc.（美國）

結論和建議

Global Morquio Syndrome Treatment Market size was valued at USD 155.6 million in 2023 and is poised to grow from USD 164.62 million in 2024 to USD 258.45 million by 2032, growing at a CAGR of 5.8% during the forecast period (2025-2032).

Morquio syndrome, categorized under mucopolysaccharidosis (MPS IV), is a rare inherited metabolic disorder primarily affecting the skeleton, characterized by the body's inability to metabolize glycosaminoglycans. The global treatment market for Morquio syndrome is witnessing significant growth driven by the rising prevalence of the condition, increased governmental and corporate support, and heightened demand for specialized medications addressing its complications. Strategic mergers and partnerships among manufacturers aim to enhance treatment options, supported by rising healthcare expenditure and technological advancements. Clinical trials are also expanding, presenting lucrative opportunities from 2022 to 2028. However, challenges such as inadequate reimbursement policies and high production costs may impede market expansion, compounded by low public awareness regarding treatment options.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Morquio Syndrome Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Morquio Syndrome Treatment Market Segmental Analysis

Global Morquio Syndrome Treatment Market is segmented by Treatment, Disease Type, Distribution Channel and region. Based on Treatment, the market is segmented into Enzyme Replacement Therapy and Others. Based on Disease Type, the market is segmented into Morquio A and Morquio B. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Morquio Syndrome Treatment Market

The Morquio Syndrome Treatment market is anticipated to experience significant growth, driven primarily by an upsurge in the number of therapeutic products entering both early and advanced research stages. There is an increasing emphasis on addressing rare diseases, which further fuels market expansion. Numerous pharmaceutical companies are actively developing new medications that, depending on their clinical trial outcomes, are expected to receive regulatory approvals. The recent authorization of elosulfase alfa (VIMIZIM) underscores the potential for additional treatments to reach the market, which is expected to stimulate interest and investment in Morquio Syndrome therapies.

Restraints in the Global Morquio Syndrome Treatment Market

One significant challenge facing the global Morquio Syndrome treatment market is the prohibitive cost associated with treatment options, notably VIMIZIM, which can reach approximately US$ 380,000 per year for patients. This financial burden limits accessibility for many who require these therapies. Furthermore, the market is hindered by a lack of awareness surrounding Morquio Syndrome in developing regions, which contributes to delayed diagnoses and treatments. Additionally, various clinical and regulatory challenges present further obstacles to market growth, complicating the landscape for both patients and healthcare providers seeking effective therapeutic solutions for this rare condition.

Market Trends of the Global Morquio Syndrome Treatment Market

The Global Morquio Syndrome Treatment market is experiencing a notable upward trend, driven by heightened research and development activities from key players and recent regulatory advancements. Pharmaceutical companies, including Ultragenyx Pharmaceutical Inc. and Shire, are actively conducting Phase 3 studies and clinical trials targeting various demographics affected by the syndrome. Moreover, innovative treatments, such as AGT 181 from ArmaGen, are emerging through clinical testing, reflecting a growing commitment to addressing this rare genetic disorder. Increased public awareness and understanding of Morquio syndrome further propel market growth, signaling a promising future for effective treatment options and improving patient outcomes.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis
• Regulatory Analysis
• Patent Analysis
• Case Studies

Global Morquio Syndrome Treatment Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Enzyme Replacement Therapy
• Others

Global Morquio Syndrome Treatment Market Size by Disease Type & CAGR (2025-2032)

• Market Overview
• Morquio A
• Morquio B

Global Morquio Syndrome Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Global Morquio Syndrome Treatment Market Size & CAGR (2025-2032)

• North America (Treatment, Disease Type, Distribution Channel)
  • US
  • Canada
• Europe (Treatment, Disease Type, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment, Disease Type, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment, Disease Type, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment, Disease Type, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• BioMarin Pharmaceuticals Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genzyme Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shire plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• JCR Pharmaceuticals Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ArmaGen, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GREEN CROSS CORP (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Concert Pharmaceuticals Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alexion Pharmaceuticals Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Actelion Pharmaceuticals Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ultragenyx Pharmaceutical Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Enzyvant Therapeutics Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations